Early lactate monitoring detects capivasertib induced type B hyperlactatemia preceding ketosis

Imagine your body as a bustling city where every cell is a factory. To keep the lights on and the machines running, these factories need fuel. Usually, they burn sugar (glucose) in a super-efficient furnace called the mitochondria, which produces clean energy and a tiny bit of exhaust. But sometimes, the city's traffic controller gets confused. In this story, the traffic controller is a protein called AKT. Think of AKT as the foreman who tells the factories how to take in sugar and how to burn it cleanly. When cancer cells grow out of control, they often hijack this foreman, making the factories run wild. To stop them, doctors use special drugs called AKT inhibitors, which essentially put the foreman on a break. The goal is to starve the cancer, but here's the twist: when you pause the foreman, the factories don't just stop; they sometimes get confused and start burning fuel in a messy, inefficient way that creates a lot of toxic exhaust. This paper explores a specific case where this "messy exhaust" became a hidden danger, showing us that we need to watch out for it before it causes a city-wide blackout.

---

The Case of the Silent Smoke

Meet a 79-year-old woman with metastatic breast cancer. She was fighting her battle with a powerful new weapon: a drug called capivasertib (let's call it "Cap" for short), paired with another medicine called capecitabine. Cap is designed to stop the cancer's growth by turning off that AKT foreman we mentioned. For the first 10 days, everything seemed okay. But on day 11, the patient's blood sugar spiked to a dangerous 334 mg/dL.

Now, usually, when blood sugar gets that high, doctors worry about something called ketosis. Think of ketosis as the body's emergency backup generator kicking in when it can't use sugar; it burns fat instead, creating "ketones" as exhaust. This is a well-known risk with high blood sugar. But here is where this story gets weird and important: this patient had almost no ketones. Instead, she had a massive, life-threatening buildup of something else: lactate.

Lactate is like the smoggy, toxic exhaust from a car engine that's sputtering because it's trying to burn fuel without enough oxygen. In this case, the patient's body was producing lactate at a high rate, even though she wasn't short of oxygen. This is called "Type B hyperlactatemia." It's a rare and dangerous condition where the body's metabolism gets stuck in a loop, churning out toxic waste instead of clean energy. The patient was rushed to the hospital because her lactate levels were sky-high, even though she didn't have the usual signs of a diabetic emergency like ketones.

What the Doctors Did and Found

The medical team at the Japanese Red Cross Society Wakayama Medical Center stopped the Cap drug immediately. Within four days, her blood sugar dropped back to a normal 100 mg/dL, and she was sent home. But the story didn't end there. When they tried to restart the drug at a lower dose (200 mg/day) a week later, the same thing happened again. Every time she started a new cycle of the drug, her lactate levels would creep up around day 4, but she felt fine—no symptoms, no ketones, just a silent spike in the toxic exhaust.

The doctors noticed a pattern: the lactate spikes were happening before any other symptoms appeared. They were also able to fix the problem quickly by pausing the drug for just three days, and over three months, the body seemed to get used to it, and the spikes got smaller and smaller.

The Big Takeaway

This paper suggests that capivasertib can cause a specific type of metabolic trouble where the body dumps lactate into the blood without making ketones. The authors explain that when you block the AKT protein, the cells can't process sugar properly. Instead of burning it cleanly in the mitochondria, the sugar gets stuck and turns into lactate. Because the body still has plenty of insulin (unlike in typical diabetic emergencies), it doesn't switch to burning fat, so no ketones are made. The result is a silent buildup of lactate that can become dangerous very quickly.

The most important lesson here is about timing. The paper argues that if a patient on this drug gets high blood sugar, doctors shouldn't just check for ketones. They need to check for lactate, too, and do it early. In this case, the lactate showed up before the patient felt sick or before ketones could build up. By catching this "silent smoke" early, the doctors were able to pause the treatment, fix the metabolic mess, and eventually get the patient back on the drug safely. It's a reminder that when you change how a cell burns fuel, you have to watch the exhaust carefully, because sometimes the most dangerous fumes are the ones you can't smell.